PT - JOURNAL ARTICLE AU - Jourdain, Marine AU - Benchaib, Mehdi AU - Ploin, Dominique AU - Gillet, Yves AU - Javouhey, Etienne AU - Horvat, Côme AU - Massoud, Mona AU - Butin, Marine AU - Claris, Olivier AU - Lina, Bruno AU - the VRS study group in Lyon AU - Casalegno, Jean-Sebastien TI - Identifying the target population for primary Respiratory Syncytial Virus two-step prevention in infants: Normative Outcome of Hospitalisation Assessment for Newborns (NOHAN) AID - 10.1101/2022.02.08.22270569 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.08.22270569 4099 - http://medrxiv.org/content/early/2022/02/15/2022.02.08.22270569.short 4100 - http://medrxiv.org/content/early/2022/02/15/2022.02.08.22270569.full AB - Background Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection related hospitalisations in infants (RSVh). Most of these infants are younger than 6 months old with no known risk factors. An efficient RSVh prevention program should address both mothers and infants, relying on Non-Pharmaceutical (NPI) and Pharmaceutical Interventions (PI). This study aimed at identifying the target population for these two interventions.Methods Laboratory-confirmed RSV-infected infants hospitalised during the first 6 months of life were enrolled from the Hospices Civils de Lyon birth cohort (2014 to 2018). Clinical variables related to pregnancy and birth (sex, month of birth, birth weight, gestational age, parity) were used for descriptive epidemiology, multivariate logistic regression, and predictive score development.Findings Overall, 616 cases of RSVh in 45 648 infants were identified. Being born before the epidemic season, prematurity, and multiparity were independent predictors of RSVh. Infants born in January or June to August with prematurity and multiparity, and those born in September or December with only one other risk factor (prematurity or multiparity) were identified as moderate-risk, identifying the mothers as candidates for a first level NPI prevention program. Infants born in September or December with prematurity and multiparity, and those born in October or November were identified as high-risk, identifying the mothers and infants as candidates for a second level (NPI and PI) intervention.Interpretation It is possible to determine predictors of RSVh at birth, allowing to enrol early the target population in a two-level RSV prevention intervention.Funding None.Evidence before this study In infants, the global burden of disease caused by the respiratory syncytial virus (RSV) is increasingly recognised. Nowadays the prevention programs are limited to the only licensed drug, Palivizumab, a humanised monoclonal antibody that shows some benefit in preventing RSV in high-risk infants. With the recent encouraging progress obtained using a maternal vaccine candidate and long half-life monoclonal antibodies administered to newborns, as well as the impact of Covid-19 non-pharmaceutical interventions on the RSV epidemic, there is an urgent need to revisit this prevention paradigm from a much broader perspective.Added value of this study Using a hospital birth cohort (NOHAN strategy) split into a training and a testing dataset, we were able to determine strong maternal and newborn predictors for the risk of RSV hospitalisation. Month of birth, multiparity, and prematurity were sufficient to accurately identify low-, moderate-, and high-risk groups in the validating cohort.Implications of all the available evidence Using the NOHAN strategy, future parents could be enrolled early during pregnancy follow-up in a health-related behaviour change program and then be proposed a vaccine boost for the pregnant women or neutralizing monoclonal antibodies for the newborns. The thresholds for triggering each intervention can be adjusted to the local epidemiology, the resources available, and the evolving evidence concerning the cost-efficiency of the future interventions. Stakeholders, healthcare professionals and policy makers must acknowledge this opportunity when designing the future of RSV prevention programs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Parents of infants for whom hospitalisation data were used were informed of the study (aim of the study, use of anonymised data, right to refuse participation) by postal mail. After this first contact, data were anonymised. Authorisation from Scientific and Ethical Committee of Hospices Civils de Lyon (Comite Scientifique et ethique des Hospices Civils de LYON CSE HCL, IRB 00013204; Pr Cyrille Confavreux) was obtained on 28/09/2021I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAggregated data are available on reasonable request.